Browse the evidence

Higher maximum semaglutide dose was associated with lower post-landmark risk of all-cause mortality (RR 0.42, p<0.001) and composite cardiovascular events (RR 0.51, p<0.001).

Practitioners should consider maximizing semaglutide dosage to enhance cardiovascular outcomes.

Semaglutide was associated with lower cardiovascular events than metformin, DPP-4 and SGLT2 inhibitors.

Semaglutide may be a preferable option for patients at risk of cardiovascular events compared to other medications.

There is a risk of excessive reduction in skeletal muscle mass (SMM) with GLP-1-based therapies.

Practitioners should monitor muscle mass in patients using GLP-1 therapies to mitigate risks of sarcopenia.

Cricket protein ingestion results in higher postprandial blood amino acid concentration compared to beef protein.

Insect protein may be more effective than some traditional animal proteins for amino acid delivery.

There is no difference in skeletal muscle anabolism between insect and animal protein sources.

Both insect and animal proteins can be used interchangeably for muscle building.

Creatine supplementation demonstrated non-significant effects on muscle strength (SMD = 0.03, 95% CI: -0.35, 0.42) but yielded the most pronounced improvement in muscle mass (MD = 2.18, 95% CI: 0.92, 3.44).

Creatine may be beneficial for increasing muscle mass in older adults, but its effect on strength is not significant.

The weekend warrior (WW) physical activity pattern is associated with significantly lower odds of sarcopenia compared to regularly active (RA) individuals (OR 0.25; 95% CI, 0.11-0.56).

Promoting weekend high-intensity workouts may be beneficial for older adults to lower sarcopenia risk.

Obesity-related hypertension is a significant contributor to cardiovascular morbidity and mortality.

Healthcare providers should prioritize addressing obesity to mitigate hypertension and related cardiovascular risks.

Up to 40% of weight loss following treatment with GLP-1RA is accounted for by lean mass.

Clinicians should be aware of potential lean mass loss when prescribing GLP-1RA therapies.

GLP-1 RA use was associated with significantly lower rates of re-tear (RR = 0.699, p < 0.001).

Practitioners may consider GLP-1 RAs as beneficial for reducing re-tear rates in rotator cuff repair patients.

Der Taillenumfang und das Verhältnis von Taillenumfang zu Hüft- oder Körpergröße sind wichtige Prädiktoren für kardiovaskuläre Risiken.

Health practitioners should consider waist measurements in assessing cardiovascular risk.

Participants with 3 and 6-7 cardiovascular risk factors controlled had lower risks of all-cause mortality, with HRs of 0.77 and 0.43, respectively.

Practitioners should encourage patients to manage multiple cardiovascular risk factors to reduce mortality risk.

Improved control of cardiovascular risk factors is associated with reduced mortality, with an HR of 0.86 compared to stable low control.

Encouraging improvements in cardiovascular risk factor control can significantly lower mortality risk.

Participants in the highest quartile of time-weighted average risk factor control had 47% lower mortality compared to those in the lowest quartile.

Maintaining high levels of cardiovascular risk factor control is crucial for reducing mortality risk.

Body types influence variations in fat storage, muscle development, and energy expenditure.

Understanding body types can help tailor fitness and nutrition programs.

Data on bone mineral density (BMD) parameters are scarce, with a possible benefit from a high-protein diet.

Practitioners may consider high-protein diets for potential benefits to bone health, but more research is needed.

Gastrointestinal adverse events were reported in 79.6% of the cagrilintide-semaglutide group and 39.9% in the placebo group.

Clinicians should monitor for gastrointestinal side effects in patients receiving cagrilintide-semaglutide.

Gastrointestinal adverse events were more common with oral semaglutide than with placebo (74.0% vs. 42.2%).

Clinicians should monitor for gastrointestinal side effects in patients taking oral semaglutide.

Gastrointestinal adverse effects were the most commonly reported side effects of retatrutide.

Clinicians should monitor for gastrointestinal side effects in patients treated with retatrutide.

Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose.

Clinicians should monitor for gastrointestinal side effects when prescribing maridebart cafraglutide.

The restore diet reduced gut microbiome diversity but enhanced the persistence of L. reuteri strain.

Practitioners should note that while diversity may decrease, specific beneficial strains can be enhanced through targeted dietary interventions.

Prolonged, intense weight-bearing exercise can increase intestinal permeability but effects are transient.

While intense exercise can temporarily affect gut health, these effects are not long-lasting.

Semaglutide showed a favorable hepatic safety profile with no discontinuations due to liver enzyme elevations.

Semaglutide can be considered safe for liver health in the studied population.

Common cardiovascular conditions, such as heart failure with preserved ejection fraction, can be conceptualized as a consequence of accelerated aging.

Understanding the link between aging and heart failure can guide prevention and management strategies.